Page last updated: 2024-10-30

qx-314 and Bone Cancer

qx-314 has been researched along with Bone Cancer in 1 studies

QX-314: triethyl analog of lidocaine; RN & NM refer to ion

Research Excerpts

ExcerptRelevanceReference
"The aim of this study was to determine whether systemic administration of QX-314 reduces bone cancer pain through selective inhibition of transient receptor potential vanilloid subfamily 1 (TRPV1)-expressing afferents."7.83Systemic QX-314 Reduces Bone Cancer Pain through Selective Inhibition of Transient Receptor Potential Vanilloid Subfamily 1-expressing Primary Afferents in Mice. ( Fuseya, S; Kawamata, M; Kawamata, T; Minemura, H; Yamamoto, K; Yamaori, S, 2016)
"The aim of this study was to determine whether systemic administration of QX-314 reduces bone cancer pain through selective inhibition of transient receptor potential vanilloid subfamily 1 (TRPV1)-expressing afferents."3.83Systemic QX-314 Reduces Bone Cancer Pain through Selective Inhibition of Transient Receptor Potential Vanilloid Subfamily 1-expressing Primary Afferents in Mice. ( Fuseya, S; Kawamata, M; Kawamata, T; Minemura, H; Yamamoto, K; Yamaori, S, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fuseya, S1
Yamamoto, K1
Minemura, H1
Yamaori, S1
Kawamata, T1
Kawamata, M1

Other Studies

1 other study available for qx-314 and Bone Cancer

ArticleYear
Systemic QX-314 Reduces Bone Cancer Pain through Selective Inhibition of Transient Receptor Potential Vanilloid Subfamily 1-expressing Primary Afferents in Mice.
    Anesthesiology, 2016, Volume: 125, Issue:1

    Topics: Anesthetics, Local; Animals; Behavior, Animal; Bone Neoplasms; Cyclic AMP Response Element-Binding P

2016